BIOPHARMA
By
Can Novo Nordisk’s New Semaglutide and Obesity Pipeline Data at EASD 2025 Redefine ‘Food Noise’ Control, Body Composition, and Cardiovascular Outcomes?
Key Highlights: Scientific Momentum at EASD 2025Novo Nordisk will present 35 abstracts across its diabetes and obesity portfolio…
Could Pfizer and BioNTech’s LP.8.1-Adapted COMIRNATY® Redefine COVID-19 Protection for High-Risk Adults in 2025-2026?
Key Insights: Robust Phase 3 Findings for High-Risk PopulationsThe topline results from the Phase 3 clinical trial included…
Will Merck’s CAPVAXIVE® 21-Valent Vaccine Set a New Benchmark in Pediatric Pneumococcal Protection After Phase 3 Success?
Key Highlights Promising Phase 3 Data from STRIDE-13 TrialMerck announced that CAPVAXIVE demonstrated robust immunogenicity and safety in…
Could Sanofi’s One-Time Gene Therapy SAR402663 Transform Treatment for Neovascular Age-Related Macular Degeneration?
Key Highlights A Major Step Forward in Retinal Disease InnovationThe FDA’s Fast Track designation underscores the urgent need…
Is Sanofi Strengthening Its Alzheimer’s Pipeline with a $1.04 Billion Partnership with South Korea’s ADEL?
Paris – Sanofi, the global pharmaceutical company, has announced a strategic collaboration with South Korea-based biotech ADEL to…
Could Roche’s Giredestrant Become the New Standard for Early-Stage ER-Positive Breast Cancer?
Basel, Switzerland – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the Phase III lidERA…
